News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Hikma Pharmaceuticals To Buy Generic Cancer Drug Business Ribosepharm For $45 Million
January 24, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (AFX) - Generic drug maker Hikma Pharmaceuticals PLC has agreed to buy Germany's Ribosepharm, which specialises in selling and marketing cancer treatments, for 45 mln usd.
>>>
Discuss This Story
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
IN PARTNERSHIP WITH CRESSET
Why AI Won’t Save the 90% of Clinical Trials That Still Fail
August 21, 2025
·
1 min read
·
Lori Ellis
GLP-1
Novo Teams Up With GoodRx for Lower-Price GLP-1s, Giving DTC Another Shot
August 18, 2025
·
1 min read
·
Annalee Armstrong
Drug pricing
Lilly Aims To Raise Europe Drug Prices in Response to Trumps’ Most Favored Nation Policy
August 14, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Tang Capital’s Concentra on Buyout Binge With Plenty of Biotech Fodder
August 13, 2025
·
4 min read
·
Annalee Armstrong
